Product Details
Synonyms
CLEC12A, MICL, CLL-1, CLL1, DCAL2, DCAL-2, CD371
Source
PE-Labeled Human CLEC12A Protein, His Tag (C-terminus) (CLA-HP2H4) is produced via site-specific conjugation of PE to Human CLEC12A, His Tag under optimal conditions with a proprietary technology. Human CLEC12A Protein, His Tag (C-terminus) (CLA-HP2H4) is expressed from human 293 cells (HEK293). It contains AA His 65 - Ala 265 (Accession # Q5QGZ9-2).
Predicted N-terminus: His 65
Request for sequenceMolecular Characterization

Other Tags and Version Biotin & Other Labeled Version
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 27.3 kDa.
Conjugate
PE
Excitation Wavelength: 488 nm / 561 nm
Emission Wavelength: 575 nm
Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4, 0.5% BSA with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please protect from light and avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
Customers Also Viewed
Performance Data
Bioactivity-FACS

5e5 of Anti-CLEC12A/CLL-1 CAR-293 cells were stained with 100 μL of 1:25 dilution (4 μL stock solution in 100 μL FACS buffer) of PE-Labeled Human CLEC12A / MICL / CLL-1 Protein, His Tag (C-terminus) (Cat. No. CLA-HP2H4) and negative control protein respectively. PE signal was used to evaluate the binding activity (QC tested).
Protocol
Customer Reviews Writing Reviews

Background
Recent Advances
- English Name:
C-Type lectin domain family 12 member A
- Category:
- Approved Drugs:
0 Details
- Drugs in Clinical Trials:
26 Details
- Highest Development Stage:
Phase 2 Clinical



















